NCT07039604 Real-World Study of PADN for the Treatment of PAH
| NCT ID | NCT07039604 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pulnovo Medical (Wuxi) Co., Ltd. |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-03-19 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Real-World Study of PADN for the Treatment of PAH
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with PAH and received PADN procedure since March 2024. 2. No contraindications to procedure. 3. Able to provide informed consent and authorize use of health/research data. 4. Compliant with treatment and follow-up requirements. Exclusion Criteria: None specified.
Frequently Asked Questions
Who can join the NCT07039604 clinical trial?
This trial is open to participants of all sexes, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07039604 currently recruiting?
Yes, NCT07039604 is actively recruiting participants. Visit ClinicalTrials.gov or contact Pulnovo Medical (Wuxi) Co., Ltd. to inquire about joining.
Where is the NCT07039604 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07039604 clinical trial?
NCT07039604 is sponsored by Pulnovo Medical (Wuxi) Co., Ltd.. The trial plans to enroll 200 participants.